Low (#3/2+#0/0) (%) Medium (#3/1+#2/2+#1/1) (%) High (#2/1+#1/2) (%) Missing data (%)
Age group                
<65 86 (65.6) 23 (17.6) 18 (13.7) 4 (3.1)
65+ 91 (68.4) 27 (20.3) 14 (10.5) 1 (0.8)
Sex                
Male 91 (66.9) 26 (19.1) 15 (11.0) 4 (2.9)
Female 86 (67.2) 24 (18.8) 17 (13.3) 1 (0.8)
Node status                
N0 165 (68.5) 43 (17.8) 28 (11.6) 5 (2.1)
N+ 10 (50.0) 6 (30.0) 4 (20.0) 0 (0.0)
NX 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0)
Tumor thickness1                
0-0.99 mm 39 (81.2) 4 (8.3) 4 (8.3) 1 (2.1)
1-1.99 mm 37 (67.3) 11 (20.0) 5 (9.1) 2 (3.6)
2-2.99 mm 26 (83.9) 3 (9.7) 2 (6.5) 0 (0.0)
3-3.99 mm 9 (47.4) 3 (15.8) 7 (36.8) 0 (0.0)
4+ mm 20 (41.7) 19 (39.6) 9 (18.8) 0 (0.0)
Missing data 46 (73.0) 10 (15.9) 5 (7.9) 2 (3.2)
Clark level                
II 42 (73.7) 8 (14.0) 5 (8.8) 2 (3.5)
III 24 (77.4) 3 (9.7) 3 (9.7) 1 (3.2)
IV 57 (74.0) 13 (16.9) 6 (7.8) 1 (1.3)
V 46 (60.5) 16 (21.1) 13 (17.1) 1 (1.3)
Missing data 3 (18.8) 8 (50.0) 5 (31.2) 0 (0.0)
Histopathology 5 (71.4) 2 (28.6) 0 (0.0) 0 (0.0)
NM                
SSM 44 (63.8) 15 (21.7) 9 (13.0) 1 (1.4)
In situ 64 (68.1) 15 (16.0) 13 (13.8) 2 (2.1)
Others 35 (71.4) 7 (14.3) 5 (10.2) 2 (4.1)
Missing data 15 (57.7) 10 (38.5) 1 (3.8) 0 (0.0)
Ulceration 19 (73.1) 3 (11.5) 4 (15.4) 0 (0.0)
No ulceration                
Ulceration 96 (69.1) 21 (15.1) 20 (14.4) 2 (1.4)
Missing data 44 (62.9) 16 (22.9) 9 (12.9) 1 (1.4)
Table 3: Distribution (number and percentage) of risk groups dying from malignant melanoma as defined by MITF expression (#fraction/intensity) in the whole sample.